Proteomic analysis of tissue samples in translational breast cancer research

Research output: Contribution to journal › Review › Research › peer-review

Standard

Proteomic analysis of tissue samples in translational breast cancer research. / Gromov, Pavel; Moreira, José; Gromova, Irina.

In: Expert Review of Proteomics, Vol. 11, No. 3, 2014, p. 285-302.

Research output: Contribution to journal › Review › Research › peer-review

Harvard

Gromov, P, Moreira, J & Gromova, I 2014, 'Proteomic analysis of tissue samples in translational breast cancer research', Expert Review of Proteomics, vol. 11, no. 3, pp. 285-302. https://doi.org/10.1586/14789450.2014.899469

APA

Gromov, P., Moreira, J., & Gromova, I. (2014). Proteomic analysis of tissue samples in translational breast cancer research. Expert Review of Proteomics, 11(3), 285-302. https://doi.org/10.1586/14789450.2014.899469

Vancouver

Gromov P, Moreira J, Gromova I. Proteomic analysis of tissue samples in translational breast cancer research. Expert Review of Proteomics. 2014;11(3):285-302. https://doi.org/10.1586/14789450.2014.899469

Author

Gromov, Pavel ; Moreira, José ; Gromova, Irina. / Proteomic analysis of tissue samples in translational breast cancer research. In: Expert Review of Proteomics. 2014 ; Vol. 11, No. 3. pp. 285-302.

Bibtex

@article{e591a927f66946d3a79a66397743f574,
title = "Proteomic analysis of tissue samples in translational breast cancer research",
abstract = "In the last decade, many proteomic technologies have been applied, with varying success, to the study of tissue samples of breast carcinoma for protein expression profiling in order to discover protein biomarkers/signatures suitable for: characterization and subtyping of tumors; early diagnosis, and both prognosis and prediction of outcome of chemotherapy. The purpose of this review is to critically appraise what has been achieved to date using proteomic technologies and to bring forward novel strategies - based on the analysis of clinically relevant samples - that promise to accelerate the translation of basic discoveries into the daily breast cancer clinical practice. In particular, we address major issues in experimental design by reviewing the strengths and weaknesses of current proteomic strategies in the context of the analysis of human breast tissue specimens.",
author = "Pavel Gromov and Jos{\'e} Moreira and Irina Gromova",
year = "2014",
doi = "10.1586/14789450.2014.899469",
language = "English",
volume = "11",
pages = "285--302",
journal = "Expert Review of Proteomics",
issn = "1478-9450",
publisher = "Taylor & Francis",
number = "3",

}

RIS

TY - JOUR

T1 - Proteomic analysis of tissue samples in translational breast cancer research

AU - Gromov, Pavel

AU - Moreira, José

AU - Gromova, Irina

PY - 2014

Y1 - 2014

N2 - In the last decade, many proteomic technologies have been applied, with varying success, to the study of tissue samples of breast carcinoma for protein expression profiling in order to discover protein biomarkers/signatures suitable for: characterization and subtyping of tumors; early diagnosis, and both prognosis and prediction of outcome of chemotherapy. The purpose of this review is to critically appraise what has been achieved to date using proteomic technologies and to bring forward novel strategies - based on the analysis of clinically relevant samples - that promise to accelerate the translation of basic discoveries into the daily breast cancer clinical practice. In particular, we address major issues in experimental design by reviewing the strengths and weaknesses of current proteomic strategies in the context of the analysis of human breast tissue specimens.

AB - In the last decade, many proteomic technologies have been applied, with varying success, to the study of tissue samples of breast carcinoma for protein expression profiling in order to discover protein biomarkers/signatures suitable for: characterization and subtyping of tumors; early diagnosis, and both prognosis and prediction of outcome of chemotherapy. The purpose of this review is to critically appraise what has been achieved to date using proteomic technologies and to bring forward novel strategies - based on the analysis of clinically relevant samples - that promise to accelerate the translation of basic discoveries into the daily breast cancer clinical practice. In particular, we address major issues in experimental design by reviewing the strengths and weaknesses of current proteomic strategies in the context of the analysis of human breast tissue specimens.

U2 - 10.1586/14789450.2014.899469

DO - 10.1586/14789450.2014.899469

M3 - Review

C2 - 24837673

VL - 11

SP - 285

EP - 302

JO - Expert Review of Proteomics

JF - Expert Review of Proteomics

SN - 1478-9450

IS - 3

ER -

ID: 125796752